Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.

The combined use of 2'-deoxy-5-azacytidine with cisplatin or 4-hydroperoxycyclophosphamide in vitro frequently resulted in synergistic cytotoxicity against a panel of six human cell lines. This enhanced cell killing occurred at drug concentrations that are clinically achievable. Synergy was also seen if the sequence of drug administration was altered, implying that a temporal overlap between the drugs was necessary, but that the actual biochemical lesions induced by each agent were probably unique, and interacted in an as yet undefined manner. Of further interest was the observation that at least one of the synergistic pairs was active against five of the six cell lines tested. 2'-Deoxy-5-azacytidine incorporation as assessed by the level of gross genomic DNA methylation did not appear to correlate with the synergistic cytotoxicity observed. Thus, we could not discern a clear relationship between the degree of DNA hypomethylation and the observed synergies, although DNA hypomethylation frequently occurred when synergy was demonstrated. The practical usefulness of these drug combinations has not yet been tested and awaits appropriate clinical trials both to assess the tumoricidal effects and possible increased toxicity.

[1]  C. Bell,et al.  Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. , 1989, Cancer research.

[2]  K. Tew,et al.  Glutathione s transferases and anticancer drug resistance , 1988 .

[3]  R. Fram,et al.  Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells. , 1987, Biochemical pharmacology.

[4]  I. Fidler,et al.  Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. , 1987, Journal of the National Cancer Institute.

[5]  B. Teicher,et al.  Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[6]  H. Pinedo,et al.  Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. , 1986, Cancer research.

[7]  H. Pinedo,et al.  Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin , 1986, Clinical pharmacology and therapeutics.

[8]  J. Trent,et al.  Comparative properties of five human ovarian adenocarcinoma cell lines. , 1985, Cancer research.

[9]  K. Kohn,et al.  DNA alkali-labile sites induced by incorporation of 5-aza-2'-deoxycytidine into DNA of mouse leukemia L1210 cells. , 1985, Cancer research.

[10]  T. Chou,et al.  Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. , 1985, Cancer research.

[11]  I. Fidler,et al.  A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. , 1984, Journal of the National Cancer Institute.

[12]  P. Jones,et al.  Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants. , 1983, Cancer research.

[13]  F. Rauscher,et al.  Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity. , 1983, Cancer research.

[14]  P. Wilkinson Pharmacologic Principles of Cancer Treatment , 1983, British Journal of Cancer.

[15]  D. Kufe,et al.  DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin. , 1982, Cancer research.

[16]  J. Christman,et al.  Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. , 1982, The Journal of biological chemistry.

[17]  R. Snyder,et al.  Application of arabinofuranosyl cytosine in the kinetic analysis and quantitation of DNA repair in human cells after ultraviolet irradiation. , 1981, Biophysical journal.

[18]  R. Craig,et al.  Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. , 1980, Cancer research.

[19]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[20]  T. F. Patton,et al.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man. , 1978, Cancer treatment reports.

[21]  T. Chou,et al.  On the determination of availability of ligand binding sites in steady-state systems. , 1977, Journal of theoretical biology.

[22]  V. Devita,et al.  The use of drugs in combination for the treatment of cancer: rationale and results. , 1973, The New England journal of medicine.

[23]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[24]  Paul Talalay,et al.  Analysis of combined drug effects: a new look at a very old problem , 1983 .

[25]  R. Kerbel,et al.  Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. , 1983, Cancer Research.

[26]  B. Barlogie,et al.  Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. , 1981, Cancer research.